Reckitt Benckiser Pharmaceuticals spinoff expected by end of the year
Richmond-based Reckitt Benckiser Pharmaceuticals Inc. (RBP) should be spun-off from its parent company by the end of the year, the company said Tuesday.
The pharmaceutical company should be separated from United Kingdom-based Reckitt Benckiser Group plc (RB) by Dec. 31. RB, a consumer goods company, announced the spinoff plans in July.
RBP offers medicine to treat opioid dependence, including Suboxone Sublingual Film, a dissolvable film which is placed under the tongue to help reduce opioid withdrawals and cravings. It also recently partnered with AntiOp Inc. to develop a nasal spray to help treat opioid overdoses.
RBP will operate independently under Indivior PLC, which will be listed on the London Stock Exchange.